We are developing life-saving drug therapies to combat Chronic Kidney Disease (CKD)

"If I could put time in a bottle..."

- Jim Croce

That's exactly our intention.

To improve health-span for patients with end-stage kidney disease.

3-5

years average wait time for a kidney transplant

American Society of Nephrology

> 50%

of CKD patients die within 5 years of dialysis treatment

American Society of Nephrology

↗ 8%

annual growth rate of CKD patients worldwide (3-4% in the US)

American Society of Nephrology

660,000 patients are currently on dialysis in the U.S. Most do not survive long enough to receive a kidney transplant (National Kidney Foundation)

Dialysis is the current standard of care prior to kidney transplantation. However, its' efficacy and outcomes are poor and come with a myriad of negative side effects. Our intention is to develop a new class of drug therapies that will integrate seamlessly into dialysis treatment. We are targeting known biology that positively regulates kidney function, which dialysis does not address.

Ultimately, CKD affects much more than the kidneys.

When our kidneys don’t function properly, they are unable to filter waste and toxins. They also are unable to provide vital nutrients, vitamins and hormones. These hallmarks of kidney failure damage other key organs and lead to further complications and life-threatening diseases, with the predominant co-morbidity being cardiovascular disease. CKD patients experience these effects in subtle and not so subtle ways, severely impairing their quality of life.

Our strategy aims to seamlessly and comfortably integrate into CKD treatment to promote improved health-span by restoring and stabilizing biological kidney functions.

Our solutions focus on preserving organs and organ functions that decline with age or as a result of illness and regulate hormone levels and other biochemical signaling between organs. We are working to identify functional parts of specific functional proteins that may be modified to improve their therapeutic applications and provide patients with a longer health-span and a higher quality of life while awaiting a kidney transplant.

Our solutions target the restoration and regulation of our body's natural proteins and hormones.


We build partnerships for good

For investors

Take part in new pathology research and commercial pharmaceutical opportunities. We are first applying our solutions to CKD with many more medical opportunities in the future to treat other chronic disease such as neurodegenerative disorders and aging pathologies.

CONTACT US

For partners

If you are interested in a partnership, collaboration, employment, or otherwise want to contact us, please reach us at info@alpha-young.com. We are always open to forming new alliances to enhance our research and clinical trials in our fight for treatment of CKD via Klotho.

CONTACT US

About us

Founded in 2019, Alpha Young is led by award-winning medical research professionals with 50+ years of expertise. Our team and advisors are dedicated to the creation of life-saving pharmaceutical products designed to unlock the therapeutic potential of biologics in patients of CKD, chronic diseases and metabolic disorders.